ENOV Stock Recent News

Wilmington, DE, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will host an investor conference call and live webcast to discuss its third quarter 2023 financial results on Tuesday, November 7, 2023 at 8:00 a.m. Eastern Time and will issue a press release earlier that morning. A presentation related to the call will be available at www.enovis.com in the “Investors” section.

Enovis (ENOV) is a Zacks Rank #5 (Strong Sell) has seen earnings estimates slide lower recently despite a good history of beating Zacks Consensus Estimate. This article will look at why this stock is a Zacks Rank #5 (Strong Sell) as it is the Bear of the Day.

Medical technology company Enovis Corp. ENOV, -0.44% said Monday it has reached an agreement to acquire LimaCorporate S.p.A., a privately held orthopedic company that specializes in restoring motion using implants, for 700 million euros ($745 million) in cash at closing and another EUR100 million in Enovis stock.

Wilmington, DE, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:

Enovis Corporation (NYSE:ENOV ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Derek Leckow - Vice President of Investor Relations Matt Trerotola - Chief Executive Officer Ben Berry - Chief Financial Officer Conference Call Participants Vik Chopra - Wells Fargo Brett Fishbin - KeyBanc Kyle Rose - Canaccord Genuity Vijay Kumar - Evercore ISI Dane Reinhardt - Baird Operator Good day, and welcome to the Enovis Second Quarter 2023 Earnings Call. [Operator Instructions] Please note, this event is being recorded.

Enovis Corporation continues to grow, with revenues increasing by 16% in the Recon part of their business, and the company's share price also growing rapidly. The company has been actively making acquisitions, including the recent purchase of Novastep, a company focusing on foot and ankle solutions, which is expected to be a key growth driver in the future. Despite potential risks such as the lack of a robotics system, Enovis is still considered a good long-term investment due to its steady growth, strong acquisitions, and expected EPS growth.

Wilmington, DE, July 11, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will host an investor conference call and live webcast to discuss its second quarter 2023 financial results on Thursday August 3, 2023 at 8:30 a.m. Eastern Time and will issue a press release earlier that morning. A presentation related to the call will be available at www.enovis.com in the “Investors” section.

Wilmington, DE, June 02, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences in June:

Enovis Corporation (NYSE:ENOV ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Derek Leckow - Vice President of Investor Relations Matt Trerotola - Chief Executive Officer Ben Berry - Chief Financial Officer Conference Call Participants Vik Chopra - Wells Fargo Kyle Rose - Canaccord Genuity Jeff Johnson - Baird Xuyang Li - Jefferies Brett Fishbin - KeyBanc Operator Good day, and welcome to the Enovis First Quarter 2023 Earnings Conference Call [Operator Instructions]. Please note, today's event is being recorded.

Enovis (ENOV) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.37 per share a year ago.